MyLymphomaTeam

Great question! Yes, the outlook for mantle cell lymphoma (MCL) has been improving, thanks to advances in treatment. The five-year overall survival rate for advanced-stage MCL is now around 65 percent, and researchers continue to find new and better ways to treat it. There are now more treatment options available than ever Show Full Answer

Great question! Yes, the outlook for mantle cell lymphoma (MCL) has been improving, thanks to advances in treatment. The five-year overall survival rate for advanced-stage MCL is now around 65 percent, and researchers continue to find new and better ways to treat it. There are now more treatment options available than ever before, including:

- Chemotherapy combinations like CHOP or hyper-CVAD
- Immunotherapy drugs
- Targeted therapies such as acalabrutinib, zanubrutinib, and venetoclax
- CAR T-cell therapy for relapsed or treatment-resistant cases
- Stem cell transplants
- Clinical trials exploring newer, more effective treatments Even for cases where MCL comes back after treatment or stops responding, there are now more options to turn to. Talking with your oncologist about which approach fits your specific situation is always the best next step.

 AI-generated responses are not a substitute for medical advice. These services are not intended to diagnose, treat, or cure any condition or disease. Always ask your doctor about specific health concerns.

Mantle Cell Lymphoma Stages: Are Most People Diagnosed at Stage 4?

Understanding Mantle Cell Lymphoma